Global Certificate in Biopharma M&A: Global Perspectives

-- ViewingNow

The Global Certificate in Biopharma M&A: Global Perspectives is a comprehensive course designed to provide learners with critical insights into the complex world of biopharma mergers and acquisitions. This certificate program is essential for professionals seeking to advance their careers in the biotech and pharmaceutical industries, where M&A activity is a key driver of growth and innovation.

5.0
Based on 5,016 reviews

3,615+

Students enrolled

GBP £ 140

GBP £ 202

Save 44% with our special offer

Start Now

ๅ…ณไบŽ่ฟ™้—จ่ฏพ็จ‹

With a focus on current industry trends, regulatory frameworks, and deal-making strategies, this course equips learners with the skills and knowledge necessary to succeed in a rapidly evolving market. Learners will gain a deep understanding of the drivers and challenges of biopharma M&A, as well as the ability to analyze and evaluate potential deals from a global perspective. In addition to gaining essential industry knowledge, learners will also have the opportunity to network with peers and industry experts, providing valuable connections and opportunities for career advancement. By completing this certificate program, learners will distinguish themselves as knowledgeable and capable professionals in the biopharma M&A field.

100%ๅœจ็บฟ

้šๆ—ถ้šๅœฐๅญฆไน 

ๅฏๅˆ†ไบซ็š„่ฏไนฆ

ๆทปๅŠ ๅˆฐๆ‚จ็š„LinkedInไธชไบบ่ต„ๆ–™

2ไธชๆœˆๅฎŒๆˆ

ๆฏๅ‘จ2-3ๅฐๆ—ถ

้šๆ—ถๅผ€ๅง‹

ๆ— ็ญ‰ๅพ…ๆœŸ

่ฏพ็จ‹่ฏฆๆƒ…

โ€ข Global Biopharma M&A Landscape: Understanding the current trends and drivers in the global biopharma M&A market, including deal structures, regulatory considerations, and cross-border transactions.
โ€ข Due Diligence in Biopharma M&A: Best practices for conducting due diligence in biopharma M&A transactions, including financial, legal, and regulatory due diligence.
โ€ข Valuation in Biopharma M&A: Methods for valuing biopharma companies, including discounted cash flow analysis, comparable company analysis, and precedent transactions.
โ€ข Integration Strategies in Biopharma M&A: Approaches for integrating acquired biopharma companies, including cultural integration, operational integration, and financial integration.
โ€ข Cross-Border Biopharma M&A: Considerations for cross-border biopharma M&A transactions, including cultural differences, regulatory considerations, and tax implications.
โ€ข Ethical Considerations in Biopharma M&A: Examination of ethical considerations in biopharma M&A transactions, including conflicts of interest, data privacy, and patient safety.
โ€ข Case Studies in Biopharma M&A: Analysis of successful and unsuccessful biopharma M&A transactions, including lessons learned and best practices.
โ€ข Future Trends in Biopharma M&A: Discussion of emerging trends and future developments in the global biopharma M&A market, including digital health, personalized medicine, and emerging markets.

่Œไธš้“่ทฏ

ๅ…ฅๅญฆ่ฆๆฑ‚

  • ๅฏนไธป้ข˜็š„ๅŸบๆœฌ็†่งฃ
  • ่‹ฑ่ฏญ่ฏญ่จ€่ƒฝๅŠ›
  • ่ฎก็ฎ—ๆœบๅ’Œไบ’่”็ฝ‘่ฎฟ้—ฎ
  • ๅŸบๆœฌ่ฎก็ฎ—ๆœบๆŠ€่ƒฝ
  • ๅฎŒๆˆ่ฏพ็จ‹็š„ๅฅ‰็Œฎ็ฒพ็ฅž

ๆ— ้œ€ไบ‹ๅ…ˆ็š„ๆญฃๅผ่ต„ๆ ผใ€‚่ฏพ็จ‹่ฎพ่ฎกๆณจ้‡ๅฏ่ฎฟ้—ฎๆ€งใ€‚

่ฏพ็จ‹็Šถๆ€

ๆœฌ่ฏพ็จ‹ไธบ่Œไธšๅ‘ๅฑ•ๆไพ›ๅฎž็”จ็š„็Ÿฅ่ฏ†ๅ’ŒๆŠ€่ƒฝใ€‚ๅฎƒๆ˜ฏ๏ผš

  • ๆœช็ป่ฎคๅฏๆœบๆž„่ฎค่ฏ
  • ๆœช็ปๆŽˆๆƒๆœบๆž„็›‘็ฎก
  • ๅฏนๆญฃๅผ่ต„ๆ ผ็š„่กฅๅ……

ๆˆๅŠŸๅฎŒๆˆ่ฏพ็จ‹ๅŽ๏ผŒๆ‚จๅฐ†่Žทๅพ—็ป“ไธš่ฏไนฆใ€‚

ไธบไป€ไนˆไบบไปฌ้€‰ๆ‹ฉๆˆ‘ไปฌไฝœไธบ่Œไธšๅ‘ๅฑ•

ๆญฃๅœจๅŠ ่ฝฝ่ฏ„่ฎบ...

ๅธธ่ง้—ฎ้ข˜

ๆ˜ฏไป€ไนˆ่ฎฉ่ฟ™้—จ่ฏพ็จ‹ไธŽๅ…ถไป–่ฏพ็จ‹ไธๅŒ๏ผŸ

ๅฎŒๆˆ่ฏพ็จ‹้œ€่ฆๅคš้•ฟๆ—ถ้—ด๏ผŸ

WhatSupportWillIReceive

IsCertificateRecognized

WhatCareerOpportunities

ๆˆ‘ไป€ไนˆๆ—ถๅ€™ๅฏไปฅๅผ€ๅง‹่ฏพ็จ‹๏ผŸ

่ฏพ็จ‹ๆ ผๅผๅ’Œๅญฆไน ๆ–นๆณ•ๆ˜ฏไป€ไนˆ๏ผŸ

่ฏพ็จ‹่ดน็”จ

ๆœ€ๅ—ๆฌข่ฟŽ
ๅฟซ้€Ÿ้€š้“๏ผš GBP £140
1ไธชๆœˆๅ†…ๅฎŒๆˆ
ๅŠ ้€Ÿๅญฆไน ่ทฏๅพ„
  • ๆฏๅ‘จ3-4ๅฐๆ—ถ
  • ๆๅ‰่ฏไนฆไบคไป˜
  • ๅผ€ๆ”พๆณจๅ†Œ - ้šๆ—ถๅผ€ๅง‹
Start Now
ๆ ‡ๅ‡†ๆจกๅผ๏ผš GBP £90
2ไธชๆœˆๅ†…ๅฎŒๆˆ
็ตๆดปๅญฆไน ่Š‚ๅฅ
  • ๆฏๅ‘จ2-3ๅฐๆ—ถ
  • ๅธธ่ง„่ฏไนฆไบคไป˜
  • ๅผ€ๆ”พๆณจๅ†Œ - ้šๆ—ถๅผ€ๅง‹
Start Now
ไธคไธช่ฎกๅˆ’้ƒฝๅŒ…ๅซ็š„ๅ†…ๅฎน๏ผš
  • ๅฎŒๆ•ด่ฏพ็จ‹่ฎฟ้—ฎ
  • ๆ•ฐๅญ—่ฏไนฆ
  • ่ฏพ็จ‹ๆๆ–™
ๅ…จๅŒ…ๅฎšไปท โ€ข ๆ— ้š่—่ดน็”จๆˆ–้ขๅค–่ดน็”จ

่Žทๅ–่ฏพ็จ‹ไฟกๆฏ

ๆˆ‘ไปฌๅฐ†ๅ‘ๆ‚จๅ‘้€่ฏฆ็ป†็š„่ฏพ็จ‹ไฟกๆฏ

ไปฅๅ…ฌๅธ่บซไปฝไป˜ๆฌพ

ไธบๆ‚จ็š„ๅ…ฌๅธ็”ณ่ฏทๅ‘็ฅจไปฅๆ”ฏไป˜ๆญค่ฏพ็จ‹่ดน็”จใ€‚

้€š่ฟ‡ๅ‘็ฅจไป˜ๆฌพ

่Žทๅพ—่Œไธš่ฏไนฆ

็คบไพ‹่ฏไนฆ่ƒŒๆ™ฏ
GLOBAL CERTIFICATE IN BIOPHARMA M&A: GLOBAL PERSPECTIVES
ๆŽˆไบˆ็ป™
ๅญฆไน ่€…ๅง“ๅ
ๅทฒๅฎŒๆˆ่ฏพ็จ‹็š„ไบบ
London School of International Business (LSIB)
ๆŽˆไบˆๆ—ฅๆœŸ
05 May 2025
ๅŒบๅ—้“พID๏ผš s-1-a-2-m-3-p-4-l-5-e
ๅฐ†ๆญค่ฏไนฆๆทปๅŠ ๅˆฐๆ‚จ็š„LinkedInไธชไบบ่ต„ๆ–™ใ€็ฎ€ๅކๆˆ–CVไธญใ€‚ๅœจ็คพไบคๅช’ไฝ“ๅ’Œ็ปฉๆ•ˆ่ฏ„ไผฐไธญๅˆ†ไบซๅฎƒใ€‚
SSB Logo

4.8
ๆ–ฐๆณจๅ†Œ